Get started
Author

Gabriela Lack

Macitentan in pulmonary hypertension due to left ventricular dysfunction
2018 · Jean-Luc Vachiéry, Marion Delcroix, et al. · European Respiratory Journal · 207
PDF
Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study
2025 · Sanjiv J. Shah, Diana Bonderman, et al. · Circulation Heart Failure · 20
Melody-1: a Pilot Study of Macitentan in Pulmonary Hypertension Due to Left Ventricular Dysfunction
2017 · Jean-Luc Vachiery, Marion Delcroix, et al. · Journal of the American College of Cardiology · 6
PDF
Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension
2024 · Nick H. Kim, Andrea M. D’Armini, et al. · Pulmonary Therapy · 4
PDF
Results of the MACiTEPH study of macitentan for the treatment of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension
2025 · David P. Jenkins, Sofija Cerovic, et al. · The Journal of Heart and Lung Transplantation · 3
Works count: 5
Citation count: 238
H-index: 3
I10-index: 2
Year
Topic
Type